Get the Stockscreener App
196.45
0.25%
0.49
After Hours:
196.45
Biogen Inc stock is traded at $196.45, with a volume of 719.02K.
It is up +0.25% in the last 24 hours and up +4.94% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$195.96
Open:
$198
24h Volume:
719.02K
Relative Volume:
0.63
Market Cap:
$29.00B
Revenue:
$9.60B
Net Income/Loss:
$1.37B
P/E Ratio:
21.08
EPS:
9.3182
Net Cash Flow:
$2.32B
1W Performance:
+0.03%
1M Performance:
+4.94%
6M Performance:
+8.05%
1Y Performance:
+48.98%
1-Day Range:
$196.34
$199.90
1-Week Range:
$184.90
$199.90
52-Week Range:
$121.05
$205.97
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
196.45 | 28.93B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,125.27 | 961.99B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
228.17 | 537.39B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
224.94 | 383.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.26 | 283.29B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
148.40 | 274.12B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Upgrade | UBS | Neutral → Buy |
| Apr-20-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-14-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-09-26 | Reiterated | H.C. Wainwright | Buy |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Downgrade | HSBC Securities | Hold → Reduce |
| Nov-06-25 | Upgrade | Stifel | Hold → Buy |
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm - Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc.BIIB - PR Newswire
Biogen receives FDA breakthrough designation for SMA therapy - Investing.com
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy - Biogen
UCB and Biogen build steroid-sparing case for lupus drug - The Pharma Letter
Biogen (BIIB) Presents Promising Data for Dapirolizumab Pegol at EULAR 2026 - GuruFocus
Mixed Lupus Win And Parkinson’s Setback Might Change The Case For Investing In Biogen (BIIB) - simplywall.st
Biogen Inc. stock (US09062X1037): Nasdaq shares steady as market digests Alzheimer’s drug outlook - AD HOC NEWS
Biogen Showcases Nephrology Advances with EMPAVELI® and Felzartamab at Major Medical Congresses - Quiver Quantitative
Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses - Biogen
Biogen Announces Upcoming Kidney Presentations at European - GlobeNewswire
Biogen Inc. stock (US09062X1037): shares firm after latest quarterly update and Alzheimer’s portfo - AD HOC NEWS
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
On the Edge of Drug Discovery - GW Today
Biogen Ends BIIB122 Parkinsons Trial And Refocuses Neurodegeneration Pipeline - Yahoo Finance
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Lancet publication adds weight to UCB and Biogen lupus drug case - The Pharma Letter
(BIIB) Risk Channels and Responsive Allocation - Stock Traders Daily
Biogen (BIIB) Unveils Positive Phase 3 Findings for Dapirolizuma - GuruFocus
Biogen, UCB Say Lupus Drug Candidate Meets Primary Endpoint in Phase 3 Trial - marketscreener.com
Biogen Inc. (BIIB) Stock Analysis: A Closer Look At Its 11.96% Upside Potential - DirectorsTalk Interviews
Biogen (BIIB) Drug Trial Achieves Key Endpoint in Lupus Study - GuruFocus
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus - Biogen
UCB and Biogen announce positive DZP phase 3 study results - marketscreener.com
A Look At Biogen (BIIB) Valuation After Earnings Beat And Parkinson’s Setback - simplywall.st
Biogen Inc. stock (US09062X1037): Italian antitrust probe and Parkinson’s trial halt in focus - AD HOC NEWS
Biogen and Denali halt BIIB122 trial for idiopathic Parkinson’s - Parkinson's News Today
Biogen investors urged to contact law firm over potential securities fraud claims. - Pluang
Why Is Biogen (BIIB) Up 3.8% Since Last Earnings Report? - Yahoo Finance
Biogen Faces Italian Investigation Over Blocking Sandoz’s Biosimilar Natalizumab - insights.citeline.com
symbol__ Stock Quote Price and Forecast - CNN
Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD? - TradingView
Biogen Inc. (BIIB) Investors with Losses are Urged to Contact The Gross Law Firm to Discuss Their Rights - GlobeNewswire
BIIB Stock Price, Quote & Chart | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Biogen Inc. stock (US09062X1037): RBC price target lift and Italian antitrust probe in focus - AD HOC NEWS
Biogen Announces Webcast of Annual Meeting of Stockholders - Biogen
Bio-Rad Laboratories stock (US09062X1037): sector focus as Elliott stake and price gains keep NYSE l - AD HOC NEWS
Biogen under investigation by Italian authorities - medwatch.com
Biogen faces Italian antitrust probe over rivalry with Sandoz for MS drugs - MSN
BIIB Maintained by RBC Capital -- Price Target Raised to $227 - GuruFocus
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Raises Target Price to $227 - Moomoo
RBC Lifts Price Target on Biogen to $227 From $222, Keeps Outperform Rating - Moomoo
Italy probes Biogen for allegedly hindering sales of rival's MS drug - Reuters
Italy probes Biogen for allegedly hindering sales of rival’s MS drug - WNWN-FM
RBC Capital raises Biogen stock price target on pipeline potential - Investing.com
Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh Cash Flow – BCBA:BIIB.CI - TradingView
Italian Watchdog Probes Biogen Over Alleged Effort to Block MS Biosimilar Rival - NAVLIN DAILY
RBC Capital raises Biogen stock price target on pipeline potential By Investing.com - Investing.com Canada
Discontinued operations of Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh – BCBA:BIIB.CI - TradingView
Debt to equity ratio of Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh – BCBA:BIIB.CI - TradingView
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):